Summary
Global Markets Direct’s, ‘Bristol-Myers Squibb Company - Product Pipeline Review - 2016’, provides an overview of the Bristol-Myers Squibb Company’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Bristol-Myers Squibb Company, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Bristol-Myers Squibb Company
- The report provides overview of Bristol-Myers Squibb Company including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Bristol-Myers Squibb Company’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Bristol-Myers Squibb Company’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Bristol-Myers Squibb Company’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Bristol-Myers Squibb Company
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bristol-Myers Squibb Company’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
Bristol-Myers Squibb Company Snapshot 7
Bristol-Myers Squibb Company Overview 7
Key Information 7
Key Facts 7
Bristol-Myers Squibb Company - Research and Development Overview 8
Key Therapeutic Areas 8
Bristol-Myers Squibb Company - Pipeline Review 18
Pipeline Products by Stage of Development 18
Pipeline Products - Monotherapy 19
Pipeline Products - Combination Treatment Modalities 20
Pipeline Products - Partnered Products 21
Pipeline Products - Out-Licensed Products 23
Bristol-Myers Squibb Company - Pipeline Products Glance 25
Bristol-Myers Squibb Company - Late Stage Pipeline Products 25
Bristol-Myers Squibb Company - Clinical Stage Pipeline Products 28
Bristol-Myers Squibb Company - Early Stage Pipeline Products 33
Bristol-Myers Squibb Company - Drug Profiles 37
nivolumab 37
daclatasvir dihydrochloride + asunaprevir 45
abatacept 47
apixaban 50
beclabuvir hydrochloride 52
brivanib alaninate 54
ipilimumab 57
ulocuplumab 62
BMS-394136 64
BMS-754807 65
BMS-833923 67
BMS-919373 69
BMS-986020 70
BMS-986036 71
BMS-986142 73
CXL-1427 74
dasatinib 75
lirilumab 78
lulizumab pegol 80
Recombinant Protein to Antagonize Fibroblast Growth Factor Receptor for Fibrosis 81
urelumab 82
BMS-986004 84
BMS-986012 85
BMS-986016 86
BMS-986089 87
BMS-986148 88
BMS-986156 89
BMS-986158 90
TD-139 91
Antibody to Target CD40 Ligand for Immunology 93
Biologic to Inhibit PD-L1 for Immunology 94
BMS-262084 95
BMS-777607 96
BMS-813160 98
BMS-906024 99
BMS-963272 101
BMS-986090 102
BMS-986104 103
BMS-986115 104
BMS-986120 105
BMS-986141 106
BMS-986147 107
BMS-986165 108
BMS-986168 109
BMS-986171 110
BMS-986186 111
FLX-925 112
KOS-1803 113
Recombinant Protein 1 to Antagonize Fibroblast Growth Factor Receptor for Fibrosis 115
Small Molecule for Oncology 116
Small Molecule to Antagonize PAR4 for Thromboembolic Disorders 117
Small Molecule to Inhibit BTK for Immunology 118
Small Molecule to Inhibit MGAT2 for Type 2 Diabetes and Obesity 119
Small Molecule to Inhibit TYK2 for Immunology 120
BMS-817378 121
ALB-109780 122
AMR-2 123
ARX-720 125
BMS-457 126
BMS-593214 127
BMS-654457 128
BMS-751324 129
BMS-795311 130
BMS-816106 131
BMS-869780 132
BMS-871 133
BMS-884775 134
BMS-986177 135
BMS-986195 136
BMS-986205 137
CXL-1036 138
Drug for Metabolic Disorders 139
Drugs to Agonize FPR-2 for Inflammation 140
DT-1154 141
F-001287 142
NP-11948 143
Small Molecule 2 to Inhibit Factor XIa for Thrombosis 144
Small Molecule for Pulmonary Arterial Hypertension 145
Small Molecule to Activate Kv7.2 for Neuropathic Pain and Diabetic Neuropathy 146
Small Molecule to Antagonize Neuropeptide Y Receptor Y1 for Obesity 147
Small Molecule to Antagonize NK1R and Block SERT for Depression 148
Small Molecule to Inhibit IAP for Melanoma 149
Small Molecule to Inhibit NS5B for Hepatitis C 150
Small Molecule to Inhibit XIAP and c-IAP for Melanoma 151
Small Molecules to Inhibit Beta Secretase 1 for Alzheimer's Disease 152
Small Molecules to Inhibit ROR-Gamma for Inflammation 153
Monoclonal Antibody Conjugates for Oncology 154
Proteins for Immunology and Oncology 155
Small Molecules to Agonize Dopamine D1 Receptor for Cognitive Impairment Associated with Schizophrenia 156
Small Molecules to Antagonize Calcitonin Gene-Related Peptide for Migraine 157
Small Molecules to Antagonize CCR2 158
Small Molecules to Inhibit IDO and TDO for Oncology 159
Small Molecules to Inhibit IDO for Oncology 160
Small Molecules to Inhibit JAK 3 for Inflammation and Autoimmune Diseases 161
Small Molecules to Inhibit JAK2 for Myeloproliferative Disorders 162
Small Molecules to Inhibit TDO for Oncology 163
Bristol-Myers Squibb Company - Pipeline Analysis 164
Bristol-Myers Squibb Company - Pipeline Products by Target 164
Bristol-Myers Squibb Company - Pipeline Products by Route of Administration 174
Bristol-Myers Squibb Company - Pipeline Products by Molecule Type 175
Bristol-Myers Squibb Company - Pipeline Products by Mechanism of Action 176
Bristol-Myers Squibb Company - Recent Pipeline Updates 183
Bristol-Myers Squibb Company - Dormant Projects 226
Bristol-Myers Squibb Company - Dormant Projects 226
Bristol-Myers Squibb Company - Discontinued Pipeline Products 231
Bristol-Myers Squibb Company - Discontinued Pipeline Products 231
Discontinued Pipeline Product Profiles 232
Bristol-Myers Squibb Company - Company Statement 237
Bristol-Myers Squibb Company - Locations And Subsidiaries 239
Head Office 239
Other Locations & Subsidiaries 239
Bristol-Myers Squibb Company - Key Manufacturing Facilities 246
Appendix 247
Methodology 247
Coverage 247
Secondary Research 247
Primary Research 247
Expert Panel Validation 247
Contact Us 247
Disclaimer 248
List of Tables
Bristol-Myers Squibb Company, Key Information 14
Bristol-Myers Squibb Company, Key Facts 14
Bristol-Myers Squibb Company - Pipeline by Indication, 2016 16
Bristol-Myers Squibb Company - Pipeline by Stage of Development, 2016 25
Bristol-Myers Squibb Company - Monotherapy Products in Pipeline, 2016 26
Bristol-Myers Squibb Company - Combination Treatment Modalities in Pipeline, 2016 27
Bristol-Myers Squibb Company - Partnered Products in Pipeline, 2016 28
Bristol-Myers Squibb Company - Partnered Products/ Combination Treatment Modalities, 2016 29
Bristol-Myers Squibb Company - Out-Licensed Products in Pipeline, 2016 30
Bristol-Myers Squibb Company - Out-Licensed Products/ Combination Treatment Modalities, 2016 31
Bristol-Myers Squibb Company - Pre-Registration, 2016 32
Bristol-Myers Squibb Company - Filing rejected/Withdrawn, 2016 33
Bristol-Myers Squibb Company - Phase III, 2016 34
Bristol-Myers Squibb Company - Phase II, 2016 35
Bristol-Myers Squibb Company - Phase I, 2016 37
Bristol-Myers Squibb Company - IND/CTA Filed, 2016 40
Bristol-Myers Squibb Company - Preclinical, 2016 41
Bristol-Myers Squibb Company - Discovery, 2016 43
Bristol-Myers Squibb Company - Pipeline by Target, 2016 171
Bristol-Myers Squibb Company - Pipeline by Route of Administration, 2016 181
Bristol-Myers Squibb Company - Pipeline by Molecule Type, 2016 182
Bristol-Myers Squibb Company - Pipeline Products by Mechanism of Action, 2016 183
Bristol-Myers Squibb Company - Recent Pipeline Updates, 2016 190
Bristol-Myers Squibb Company - Dormant Developmental Projects,2016 233
Bristol-Myers Squibb Company - Discontinued Pipeline Products, 2016 238
Bristol-Myers Squibb Company, Other Locations 246
Bristol-Myers Squibb Company, Subsidiaries 246
Bristol-Myers Squibb Company, Key Manufacturing Facilities 253
List of Figures
Bristol-Myers Squibb Company - Pipeline by Top 10 Indication, 2016 16
Bristol-Myers Squibb Company - Pipeline by Stage of Development, 2016 25
Bristol-Myers Squibb Company - Monotherapy Products in Pipeline, 2016 26
Bristol-Myers Squibb Company - Combination Treatment Modalities in Pipeline, 2016 27
Bristol-Myers Squibb Company - Partnered Products in Pipeline, 2016 28
Bristol-Myers Squibb Company - Out-Licensed Products in Pipeline, 2016 30
Bristol-Myers Squibb Company - Pipeline by Top 10 Target, 2016 171
Bristol-Myers Squibb Company - Pipeline by Route of Administration, 2016 181
Bristol-Myers Squibb Company - Pipeline by Molecule Type, 2016 182
Bristol-Myers Squibb Company - Pipeline Products by Top 10 Mechanism of Action, 2016 183
